KRAS and neoplasm: In 2016, Tran et al. reported for the first time the adoptive transfer of in vitro expanded HLA-C*08:02 restricted tumor-infiltrating lymphocytes, which contain large amounts of KRAS-G12D mutant specific T cells, in a patient with metastatic colorectal cancer, demonstrating effective anti-tumor efficacy18.